MUC1 Chimeric Protein Ligand Traps for Oncogenic Signaling Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies are inadequate in effectively targeting and inhibiting MUC1-mediated oncogenic signaling in cancer cells, as MUC1 is aberrantly overexpressed and plays a crucial role in integrating signals from key pathways like Wnt and ErbB, contributing to cellular transformation and resistance to apoptosis.
Innovation Solution
Development of chimeric proteins comprising a MUC1-extracellular (MUC1-EC) polypeptide and a carrier polypeptide, such as human immunoglobulin FC or albumin, which act as traps for endogenous MUC1 ligands, intercepting them before they bind to MUC1 on cancer cells, thereby decreasing oncogenic signaling. These proteins can be administered alone or in combination with chemotherapeutic agents or ionizing radiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then general treatment is provided, but they are inadequate in effectively targeting MUC1-mediated oncogenic signaling
Solution Approach 1:
The patent uses chimeric proteins as intermediary molecules that specifically bind to MUC1 ligands. These chimeric proteins consist of a MUC1 ligand-binding domain fused to a carrier protein, acting as a mediator that intercepts MUC1 ligands and prevents them from binding to MUC1 on cancer cells, thereby specifically targeting MUC1-mediated signaling pathways while using conventional therapy frameworks
Solution Approach 2:
The invention applies local quality by designing chimeric proteins with specific functional domains: a MUC1 ligand-binding domain that provides specific recognition and binding to MUC1 ligands, and a carrier protein domain that provides stability and pharmacokinetic properties. This localized functional differentiation enables specific targeting of MUC1-expressing tumors while maintaining overall therapeutic effectiveness
2Reliability
If MUC1 is overexpressed and integrates signals from Wnt and ErbB pathways, then oncogenic signaling is enhanced, but this contributes to cellular transformation and resistance to apoptosis
Solution Approach 1:
The chimeric proteins perform preliminary anti-action by intercepting MUC1 ligands in the circulation and extracellular space before they can bind to MUC1 receptors on cancer cell surfaces. This preemptive binding prevents the activation of downstream oncogenic signaling pathways including Wnt and ErbB pathways, thereby preventing cellular transformation and apoptosis resistance before they occur
Solution Approach 2:
The invention extracts or removes MUC1 ligands from the system by having chimeric proteins bind to them and form complexes that are cleared from circulation. This extraction of the harmful ligand prevents it from engaging in pathological interactions with MUC1 on cancer cells, thereby eliminating the source of oncogenic signaling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MUC1 chimeric proteins effectively inhibit MUC1-mediated signaling, leading to the inhibition or killing of MUC1-expressing cancer cells, potentially enhancing the efficacy of conventional cancer treatments by targeting MUC1-expressing tumors and modulating dermcidin expression and signaling.
Implementation Method 1
chimeric proteins comprising a MUC1-extracellular (MUC1-EC) polypeptide and a carrier polypeptide that function as traps for endogenous MUC1 ligands
Data Source
AI summary
The present invention provides for chimeric proteins comprising a MUC1 extracellular (MUC1-EC) polypeptide and a carrier polypeptide that function as traps for MUC1 ligands.